Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Emerging treatments for mCRPC

Emmanuel Antonarakis • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Prostate Cancer 177Lu-PSMA-617 Antibodies Checkpoint Inhibitors Enzalutamide Niraparib Nivolumab Olaparib Pembrolizumab Rucaparib Talazoparib
PROfound VISION

Emmanuel Antonarakis, MBBCh, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses emerging treatments for metastatic castration-resistant prostate cancer (mCRPC). Referencing the PROfound (NCT02987543) and VISION (NCT03511664) trials, he specifically focuses on checkpoint inhibitors, PARP inhibitors and PSMA-targeted approaches. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Emmanuel Antonarakis

3:56
PARP inhibitors: activity in BRCA1 versus BRCA2 altered mCRPC
Emmanuel Antonarakis • 12 Feb 2021
2:58
Characterization of PSA responses to bipolar androgen therapy in mCRPC
Emmanuel Antonarakis • 12 Feb 2021
1:46
Genomic and clinical features of SPOP mutations in prostate cancer
Emmanuel Antonarakis • 12 Feb 2021
3:18
KEYNOTE-199: an update on pembrolizumab for mCRPC
Emmanuel Antonarakis • 13 Feb 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals